Search clinical trials for: Xgeva

Total 62 results

mAbxience Research S.L.

Completed

A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva

Healthy Volunteers

Poland
Hellenic Society for the Study of Bone Metabolism

Completed

Denosumab for the Treatment of Adult LCH

Langerhans Cell Histiocytosis

Greece
European Organisation for Research and Treatment...
Amgen

Terminated

Reduced Dose-density of Denosumab for Unresectable GCTB (REDUCE)

Bone Giant Cell Tumor

Spain, United Kingdom, Italy, Netherlands
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (MW032)

Bone Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Bone Metastasis From Solid Tumors
Amgen

Completed

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer

Spain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama
Amgen
University of Aarhus

Completed

Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark

XGEVA Off-label Use
Leiden University Medical Center
Amgen

Recruiting

Denosumab in Subjects With Giant Cell Rich Tumors of Bone

Aneurysmal Bone Cysts | Giant Cell Granuloma | Osteoblastoma | Chondroblastoma | Chondromyxoid Fibroma

France, Italy, Netherlands
Jules Bordet Institute
Melbourne Health

Terminated

A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (D-Beyond)

Breast Neoplasms

Belgium, Australia
Amgen

Recruiting

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Giant Cell Tumor of Bone

Taiwan, China
Elizabeth Shane
Creighton University

Completed

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Adult Idiopathic Generalized Osteoporosis

United States
Alison Stopeck
Amgen

Completed

Denosumab and MRI Breast Imaging (Dmab)

Breast Cancer

United States
Taizhou Mabtech Pharmaceutical Co.,Ltd

Withdrawn

Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers

Healthy Volunteers

China
University of Manitoba
McMaster University; University of Toronto

Completed

The Efficacy of Denosumab in Active Crohn's Disease

Crohn Disease

Canada
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Terminated

Denosumab in Primary Hyperparathyroidism

Primary Hyperparathyroidism

United States
NYU Langone Health

Completed

Presurgical Trial of Denosumab in Breast Cancer

Breast Cancer

United States
Amgen

Completed

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Castrate-resistant Prostate Cancer

United Kingdom, Czech Republic
Amgen

Completed

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Hormone Refractory Prostate Cancer
Hebei Medical University Third Hospital

Unknown

Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone (D-Gct)

Giant Cell Tumor of Bone

China
Amgen
Daiichi Sankyo, Inc.

Terminated

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Breast Cancer

United States, Denmark, France, Italy, Belgium, Canada, Czechia, Germany, Netherlands, United Kingdom, Korea, Republic of, Peru, Philippines, Poland, Russian Federation, Taiwan, Spain, Australia, Hong Kong, Slovakia, Israel, Hungary, Portug... and more
Amgen

Completed

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

Renal Impairment

United States
Assistance Publique - Hôpitaux de Paris
CEREMAST

Active, not recruiting

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis (DenosuMast)

Osteoporosis | Systemic Mastocytosis

France
Cancer Trials Ireland

Terminated

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. (DICE)

Metastatic Cancer | Bone Metastases | Castration-resistant Prostate Cancer

Ireland
Massachusetts General Hospital
Emory University; University of Rochester; Amgen; University Hospitals Cleveland...

Unknown

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Multiple Myeloma

United States
Peking University People's Hospital

Completed

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts (Deno-ABC)

Recurrent Disease | Pathological Fracture | Refractory Tumor | Bone Cyst Aneurysmal
Peking University People's Hospital

Unknown

Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China

Giant Cell Tumor of Bone
Amgen

Completed

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

United States, Denmark, Poland, Canada
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Qilu Pharmaceutical Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Healthy People

China
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Terminated

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

Spinal Cord Injury | Secondary Osteoporosis

United States
Amgen

Completed

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

Healthy Volunteer

United States
Amgen

Withdrawn

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Solid Tumor | Metastatic Bone Disease
Alvotech Swiss AG

Active, not recruiting

AVT03 With Xgeva in Healthy Male Subjects

This is a Phase Study Conducted in Healthy Volunteers

South Africa
Roswell Park Cancer Institute
Amgen

Completed

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Osteoporosis | Osteopenia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States
Borstkanker Onderzoek Groep
Amgen

Withdrawn

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer (PERIDENO)

Breast Neoplasms

Netherlands
Natasha Appelman-Dijkstra

Recruiting

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) (DeFiD)

Fibrous Dysplasia | McCune Albright Syndrome

Netherlands
Hope Rugo, MD
University of California, San Francisco; Amgen

Terminated

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Early Stage Breast Cancer

United States
Institut Català d'Oncologia
Amgen

Active, not recruiting

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer (D-BIOMARK)

Stage I Breast Cancer | Breast Neoplasm Female | Stage II Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Neoplasm

Spain
Swiss Group for Clinical Cancer Research

Active, not recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

Switzerland, Germany, Austria
Luye Pharma Group Ltd.

Recruiting

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Qilu Pharmaceutical Co., Ltd.

Unknown

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Bone Metastases

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
ETOP IBCSG Partners Foundation
European Organisation for Research and Treatment of Cancer - EORTC; Amgen

Completed

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (SPLENDOUR)

Lung Cancer Non-small Cell Stage IV

Ireland, Spain, Switzerland, United Kingdom, France, Austria, Slovenia, Belgium, Italy, Germany, Poland
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Healthy

China
Australian and New Zealand Urogenital and Prostate...
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)

Renal Cell Carcinoma, Clear Cell | Metastatic Kidney Cancer

Australia
University Medical Centre Ljubljana

Enrolling by invitation

Osteoporosis in Primary Hyperparathyroidism

Primary Hyperparathyroidism | Osteoporosis

Slovenia
Luye Pharma Group Ltd.
Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Unknown

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Healthy Adults
Arbeitsgemeinschaft medikamentoese Tumortherapie
Amgen; Assign Data Management and Biostatistics GmbH

Active, not recruiting

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (DEFENCE)

Multiple Myeloma

Austria, Germany, Israel

Search clinical trials for: Xgeva

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations